Uterine fibroids statistics: how common they are by age 50, and why Black women carry the heaviest load

She was 38, and the pad she brought to the appointment was the kind sold for postpartum recovery. Heavy periods for six years. Clots that looked wrong even to her. Two emergency department visits for dizziness, a ferritin in the single digits, and a chart full of "menorrhagia: trial oral contraceptive" notes that never led to an ultrasound until she asked for one by name. The scan showed a uterus remodeled by intramural fibroids. She looked at the screen and said, "I thought everyone bled like this."

That sentence is the epidemiology of this disease in plain English. Uterine fibroids (leiomyomas) are so common that abnormal bleeding gets filed under "period problems" for years. Many women never know they have them. Others live with symptoms for more than three years on average before they seek treatment.

Ultrasound screening studies and procedure databases give unusually clean numbers on this condition. This article gathers the ones a reporter can lift with the primary source named beside them: cumulative incidence by age 50, the Black-white gap, symptom burden, hysterectomy share, uterine-sparing uptake, diagnostic delay, and annual U.S. cost.

Measure	Black women	White women
Estimated cumulative incidence by age 50 (Baird et al., 2003)	>80%	Nearly 70%
Ultrasound prevalence, asymptomatic ages 18-30 (Marsh et al., 2013)	26%	7%
Clinical diagnosis prevalence, insured cohort 2014 (Yu et al.)	18.5%	Lower than Black women (overall 9.6%)
Age-specific cumulative incidence odds ratio, Black vs white (Baird et al.)	OR 2.9 (95% CI 2.5-3.4)

Sources: Baird et al., American Journal of Obstetrics and Gynecology, 2003; Marsh et al., Fertility and Sterility, 2013; Yu et al., American Journal of Obstetrics and Gynecology, 2018.

Procedure	Inpatient share	Ambulatory surgery share
Hysterectomy	76.5%	66.8%
Myomectomy	21.9%	22.1%
Uterine fibroid embolization	1.6%	6.7%
Endometrial ablation	0.1%	4.3%

Source: Barrett ML, et al. HCUP Statistical Brief #200. Agency for Healthcare Research and Quality, 2016. Analysis limited to four selected procedures among women ages 18-54 in 13 states, 2013.

How common fibroids are by midlife

Secondary literature still understates how common fibroids are, because clinical diagnosis only counts women who get imaged or operated on. The cleanest estimate comes from screening that does not wait for symptoms.

In 2003, Baird and colleagues at the National Institute of Environmental Health Sciences published ultrasound evidence from 1,364 randomly selected members of an urban health plan, ages 35-49. Among premenopausal participants, 35% already had a prior clinical diagnosis of fibroids. Of the women with no previous diagnosis, 51% still had ultrasound evidence of tumors. Modeled to age 50, estimated cumulative incidence exceeded 80% for Black women and approached 70% for white women. The age-specific cumulative incidence curves differed sharply (odds ratio 2.9; 95% CI 2.5-3.4).

That is the number to quote when someone asks how common fibroids really are. By the end of reproductive life, most Black and white women in that screened population had developed them. The tumors are often silent. Only a subset drive bleeding, pressure, anemia, fertility problems, or surgery.

Claims-based rates look smaller because they require a medical encounter. Yu and colleagues, following women ages 18-65 in Kaiser Permanente Washington from 2005 through 2014, reported overall clinical prevalence of 9.6% in 2014, peaking at 15.9% at ages 50-54. Incidence of new diagnoses declined from 139.4 to 101.4 per 10,000 woman-years; about 90% of incident cases carried symptom-related codes. Useful for system planning. Not a substitute for ultrasound screening on biologic prevalence.

Heavy menstrual bleeding is the dominant clinical complaint. In Zimmermann and colleagues' eight-country survey of more than 21,000 women of reproductive age, those with a fibroid diagnosis reported heavy bleeding at 59.8%, versus 37.4% without a diagnosis, plus higher rates of prolonged and intermenstrual bleeding.

The racial gap starts early

The midlife gap is well known. What still surprises people is how early it appears.

Marsh and colleagues performed a pilot ultrasound study of 101 nonparous, asymptomatic women ages 18-30 with no known fibroid diagnosis. Overall prevalence of ultrasound-diagnosed fibroids was 15%. The split by race was 26% among Black women and 7% among white women. Mean fibroid size was 2.3 cm. These were early tumors in women who had not yet been told they had a problem.

Baird's later prospective work reinforces early onset. In a community-based cohort of 1,693 African American women ages 23-35 with no prior diagnosis, ultrasound at enrollment and after about 18 months found a new-fibroid incidence of 9.4% (95% CI 7.7-11.2) among 1,123 fibroid-free women with follow-up. Incidence rose with age. Indirect evidence had long suggested at least a decade earlier onset versus white women; the protocol put numbers on that trajectory.

Stewart and colleagues' national survey of symptomatic women (268 African American, 573 white, ages 29-59) found the clinical consequences. African American respondents were more likely to report severe or very severe heavy or prolonged menses (RR 1.51; 95% CI 1.05-2.18) and anemia (RR 2.73; 95% CI 1.47-5.09). They more often said fibroids interfered with physical activities (RR 1.67) and relationships (RR 2.27), and they were more likely to miss work (RR 1.77; 95% CI 1.20-2.61).

The same architecture shows up across reproductive health. Our reviews of Black maternal health disparities and women's healthcare access describe how earlier disease, delayed care, and unequal procedure choice stack rather than cancel out.

Symptom burden and daily life

Not every fibroid needs treatment. The ones that do can reorganize a woman's month.

Heavy menstrual bleeding is the lead symptom, often with clotting and iron-deficiency anemia. Pelvic pressure and urinary frequency are common. So are constipation and bulk symptoms from an enlarged uterus; dyspareunia is another frequent complaint. Reproductive effects depend heavily on location, especially submucosal disease. For the bleeding-anemia pathway, our iron-deficiency anemia statistics page tracks how often heavy periods land women in the lab with low ferritin.

Borah and colleagues' national survey of 968 women with symptomatic leiomyomas put numbers on work impact: 28% of employed respondents reported missing work because of symptoms, and 24% believed fibroids had kept them from reaching their career potential. Those are self-report figures from women already labeled with disease, and they still understate women who never reach a diagnosis.

Marsh and colleagues' 2018 population-based survey of U.S. women separated "at-risk" respondents with suggestive symptoms but no clinical diagnosis (n = 300) from diagnosed women (n = 871) and women who had undergone fibroid-related hysterectomy (n = 272). On the Uterine Fibroid Symptom and Health-Related Quality of Life instrument, at-risk women reported greater symptom severity and lower quality of life than diagnosed women. Undiagnosed disease is not mild disease. Among diagnosed women, 71% had used pharmacologic therapy and 30% had undergone a surgical or procedural treatment.

If you track cycles while waiting for evaluation, tools such as our period calculator and cycle length calculator help document bleeding days and interval length in language a clinician can use. They do not diagnose fibroids. They make the history harder to dismiss.

Measure	Estimate
Average years waited before seeking treatment	3.6
Saw 2 or more providers for diagnosis	41%
Employed respondents who missed work due to symptoms	28%
Wanted treatment that avoids invasive surgery	79%
Wanted treatments that preserve the uterus	51%

Source: Borah BJ, et al. American Journal of Obstetrics and Gynecology, 2013. National survey of 968 U.S. women ages 29-59 with self-reported symptomatic uterine leiomyomas.

How often fibroids lead to hysterectomy

Fibroids are the leading indication for hysterectomy in the United States in multiple national series, and that fact still shapes how patients hear the diagnosis. "You have fibroids" often lands as "you will lose your uterus," even when removal is not required.

Whiteman and colleagues used the National Hospital Discharge Survey for inpatient hysterectomies from 2000 through 2004. The proportion performed for uterine leiomyoma fell from 44.2% in 2000 to 38.7% in 2004. That was still the largest single indication category, nearly two in five inpatient cases. Overall inpatient hysterectomy rates drifted only slightly, from 5.4 to 5.1 per 1,000 women.

Procedure choice has shifted more than the indication share. AHRQ's HCUP Statistical Brief #200 analyzed four common surgical treatments for benign fibroids among women ages 18-54 in 13 states. In 2013, hysterectomy still dominated: 76.5% of inpatient cases and 66.8% of hospital-based ambulatory surgery visits among those four procedures. Myomectomy held roughly 22% in both settings. Embolization and ablation were small but more common outpatient: embolization 6.7% ambulatory versus 1.6% inpatient; ablation 4.3% ambulatory versus 0.1% inpatient.

Between 2005 and 2013 in that sample, the overall rate of hysterectomy for benign fibroids fell 20%, from 210.8 to 168.0 per 100,000 women ages 18-54. The drop was driven by a 52% decline in inpatient hysterectomy, while ambulatory hysterectomy rose more than fourfold. Embolization rates rose about 170% in both settings; inpatient myomectomy fell 29%. Fewer open inpatient hysterectomies. More outpatient and uterus-preserving routes. Hysterectomy remains the majority procedure when surgery happens.

Race and setting are not independent. In the 2013 HCUP snapshot, Black women were 40.3% of inpatient fibroid procedure stays but only 27.8% of ambulatory visits, while white women were 33.9% of inpatient stays and 51.4% of ambulatory visits. That pattern fits more severe disease, later presentation, less access to outpatient pathways, or some mix of all three. For broader surgery trends, see our hysterectomy rates statistics review.

Uterine-sparing options and who gets them

Patients consistently say they want options that keep the uterus when possible. In Borah's survey, 79% wanted treatments that avoid invasive surgery, 51% wanted uterus-preserving approaches, and 43% of women under 40 wanted fertility preservation. The gap is between preference and what gets offered.

Medical management is usually first line for bleeding: NSAIDs, tranexamic acid, hormonal contraception including the levonorgestrel IUD, GnRH agents with add-back therapy, and iron repletion. Those tools control symptoms for many women. They do not remove fibroids, and symptoms often return when medication stops.

Uterine-sparing procedures include myomectomy, uterine fibroid embolization (UFE), endometrial ablation in selected patients, and image-guided or energy-based options in limited centers. AHRQ's 2013 mix shows how uneven uptake still was: myomectomy about one in five surgical cases, UFE a few percent, ablation mostly outpatient and uncommon relative to hysterectomy.

A July 2024 Harris Poll for the Society of Interventional Radiology among 1,122 U.S. women (including 167 with a personal fibroid diagnosis) found that more than half of diagnosed women (53%) were presented with hysterectomy, while fewer than one in five (20%) were presented with less invasive options such as NSAIDs (19%), UFE (17%), oral contraceptives (17%), or endometrial ablation (17%). Seventeen percent believed hysterectomy was the only treatment, including 27% of women ages 18-34. Seventy-two percent of women did not know they were at risk for fibroids.

Those are specialty-society survey figures (patient-reported offer rates, not a claims census), but they match clinic experience. Hysterectomy is explained thoroughly. Embolization and medical options often arrive as afterthoughts. Marsh's 2018 survey adds a detail that should make clinicians uncomfortable: the hysterectomy cohort was most likely to have first discussed hysterectomy. Framing is not neutral.

Why care is delayed

The average 3.6-year wait before seeking treatment, from Borah et al., is one of the most quotable patient-experience numbers in this field. Forty-one percent of respondents saw two or more providers for diagnosis. That is not a rare sad story. It is the central tendency of a national sample of symptomatic women.

Ghant and colleagues later interviewed 60 women with symptomatic or recently treated fibroids to ask why delay happens. Themes clustered around a distorted sense of normal bleeding, low fibroid knowledge, low perceived personal risk, avoidance-based coping, and psychological distancing from the diagnosis. The culture of "periods are supposed to be awful" collides with a disease that thrives on under-recognition. The qualitative work does not replace the 3.6-year mean. It explains the mechanism.

Part of the delay is clinical: abnormal uterine bleeding has a long differential, and ultrasound is underused when the history already screams for imaging. Part is social: women normalize flooding because mothers and sisters flooded. Part is structural: lost wages, prior dismissal, insurance churn. The pattern rhymes with other underdiagnosed gynecologic disease. See our coverage of endometriosis diagnosis delays and medical gaslighting and diagnostic delay.

What shortens the path is straightforward. Ask about pad changes per hour and night-time flooding. Ask about clots and work or school days lost. Check a CBC and ferritin. Order pelvic ultrasound when heavy bleeding is recurrent, not after years of failed oral contraceptives. Name fibroids as a common possibility for Black women in their 20s and 30s, not only near menopause.

What fibroids cost the United States

Cardozo and colleagues' 2012 systematic review remains the standard reference for U.S. societal cost. Working in 2010 dollars, they estimated annual direct costs of surgery, hospital admissions, outpatient visits, and medications at $4.1-9.4 billion. Lost-work costs ranged from $1.55-17.2 billion. Obstetric complications attributed to fibroids added $238 million to $7.76 billion. Summed, uterine fibroids cost the United States an estimated $5.9-34.4 billion per year. Lost work, not the operating room bill, often dominated the total.

Hazimeh and colleagues revisited that framework for 2022, converting costs to 2023 dollars and incorporating population growth, changing procedure mix, newer technologies such as MRI-guided focused ultrasound, and infertility-related costs. The number of U.S. women with fibroids rose 10.6% from 2010 to 2022. Economic burden increased to as much as $41.4 billion versus the prior upper bound of $34.4 billion, and overall costs reached about $42.2 billion after the new line items. Direct medical-management costs fell while surgical costs rose. Lost work remained the largest piece. Cesarean delivery continued to drive most of the obstetric cost share (about 80% of that component on average).

Those ranges are wide because prevalence assumptions and wage estimates both move the model, as does obstetric attribution. Even the lower bound is multi-billion-dollar. For patients, the household costs are simpler: missed shifts, iron infusions, recovery weeks after surgery, and fertility treatment when submucosal fibroids complicate conception. Our infertility and IVF statistics page covers the assisted-reproduction side when fibroids sit in or distort the cavity.

Frequently asked questions